These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

680 related items for PubMed ID: 11791181

  • 1. Consequences of altered TGF-beta expression and responsiveness in breast cancer: evidence for autocrine and paracrine effects.
    Tobin SW, Douville K, Benbow U, Brinckerhoff CE, Memoli VA, Arrick BA.
    Oncogene; 2002 Jan 03; 21(1):108-18. PubMed ID: 11791181
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Transforming growth factor beta 1 (TGF beta 1) is an autocrine positive regulator of colon carcinoma U9 cells in vivo as shown by transfection of a TGF beta 1 antisense expression plasmid.
    Huang F, Newman E, Theodorescu D, Kerbel RS, Friedman E.
    Cell Growth Differ; 1995 Dec 03; 6(12):1635-42. PubMed ID: 9019169
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Deletion of one adenine base within the polyadenine tract of transforming growth factor-beta receptor type II in human MDA-MB-231 breast cancer cell line.
    Park B, Jang JS, Park K.
    Int J Oncol; 2000 Sep 03; 17(3):473-8. PubMed ID: 10938386
    [Abstract] [Full Text] [Related]

  • 9. Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function.
    Schniewind B, Groth S, Sebens Müerköster S, Sipos B, Schäfer H, Kalthoff H, Fändrich F, Ungefroren H.
    Oncogene; 2007 Jul 19; 26(33):4850-62. PubMed ID: 17297450
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
    Zhang F, Lee J, Lu S, Pettaway CA, Dong Z.
    Clin Cancer Res; 2005 Jun 15; 11(12):4512-20. PubMed ID: 15958637
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. TGF-beta promotes the establishment of renal cell carcinoma bone metastasis.
    Kominsky SL, Doucet M, Brady K, Weber KL.
    J Bone Miner Res; 2007 Jan 15; 22(1):37-44. PubMed ID: 17032147
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma.
    Yang F, Strand DW, Rowley DR.
    Oncogene; 2008 Jan 17; 27(4):450-9. PubMed ID: 17637743
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Distortion of autocrine transforming growth factor beta signal accelerates malignant potential by enhancing cell growth as well as PAI-1 and VEGF production in human hepatocellular carcinoma cells.
    Sugano Y, Matsuzaki K, Tahashi Y, Furukawa F, Mori S, Yamagata H, Yoshida K, Matsushita M, Nishizawa M, Fujisawa J, Inoue K.
    Oncogene; 2003 Apr 17; 22(15):2309-21. PubMed ID: 12700666
    [Abstract] [Full Text] [Related]

  • 19. Transcriptional deregulation of VEGF, FGF2, TGF-beta1, 2, 3 and cognate receptors in breast tumorigenesis.
    Soufla G, Porichis F, Sourvinos G, Vassilaros S, Spandidos DA.
    Cancer Lett; 2006 Apr 08; 235(1):100-13. PubMed ID: 15949894
    [Abstract] [Full Text] [Related]

  • 20. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression.
    Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT.
    J Clin Invest; 1993 Dec 08; 92(6):2569-76. PubMed ID: 7504687
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.